Steven Cramer, MD
Neuromuscular Medicine · Los Angeles, CANPI 1477633568
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $101,349 of the $112,404 with a category attached, or 90.2%. 11 manufacturers reported payments, led by Myomo, Inc at 41.7% of the total. Reporting peaked in 2022 at $28,347 and has fallen 50.4% since, to $14,059 in 2025.
Across 50 payments — averaging $2248.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myomo, Inc$47K
- Microtransponder, Inc.$19K
- Medtronic$17K
- AbbVie$15K
- Biogen$7K
- Bayer$5K
- plus $2K from 5 others
Across 2 payments — averaging $46,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sunovion Pharmaceuticals Inc.$94K
What the payments were for
- Consulting fees$101,34990%
- Speaking & faculty fees$10,0739%
- Travel & lodging$1530%
- Food & beverage$8301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myomo, Inc | 5 | $46,875 |
| Microtransponder, Inc. | 3 | $19,159 |
| Medtronic(2 entities) | 14 | $17,242 |
| AbbVie | 14 | $14,881 |
| Biogen | 7 | $7,132 |
| Bayer | 1 | $5,430 |
| Omniscient Neurotechnology America Ltd | 2 | $1,250 |
| Ipsen Biopharmaceuticals, Inc | 1 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $114 |
| Genentech USA, Inc. | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,404 in reported general payments places this provider in the 75th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neuromuscular medicine in Los Angeles
- Michael ChungLos Angeles$564
- Abel WuLos Angeles$361
- Simon ZimnowodzkiLos Angeles$62
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
- Marwa KaiseyWest Hollywood$264K
- Namita GoyalOrange$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.